ReviewNeurologia medico-chirurgica2013
Usefulness of FMISO-PET for glioma analysis.
Review in Neurologia medico-chirurgica, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Role of [18F]FMISO PET Imaging for the Evaluation of Gliomas: A Comprehensive Literature Review.Diagnostics (Basel, Switzerland) · 2026Review
- A Review of Hypoxia Imaging Using 18F-Fluoromisonidazole Positron Emission Tomography.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Review
- Prediction of Hypoxia in Brain Tumors Using a Multivariate Model Built from MR Imaging andMagnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2020Article
- Influence of the scan time point when assessing hypoxia inEuropean journal of nuclear medicine and molecular imaging · 2020Article
- The Role of Metabolic Plasticity in Blood and Brain Stem Cell Pathophysiology.Cancer research · 2020Review
- The Roles of Hypoxia Imaging UsingJournal of clinical medicine · 2019Review
- Searching for novel PET radiotracers: imaging cardiac perfusion, metabolism and inflammation.American journal of nuclear medicine and molecular imaging · 2018Review
- Review
- The role of radionuclide probes for monitoring anti-tumor drugs efficacy: A brief review.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2017Review
- Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study.European radiology · 2017Article
- Pathological analysis of the surgical margins of resected glioblastomas excised using photodynamic visualization with both 5-aminolevulinic acid and fluorescein sodium.Journal of neuro-oncology · 2017Article
- F-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapy.Seminars in nuclear medicine · 2015Review
- Therapeutic Response Assessment of High-Grade Gliomas During Early-Phase Drug Development in the Era of Molecular and Immunotherapies.Cancer journal (Sudbury, Mass.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioma is one of the most common brain tumors in adults. Its diagnosis and management have been determined by histological classifications. It is difficult to establish new paradigms because the pathology has matured and a great deal of knowledge has accumulated. On the other hand, we understand that there are limitations to this gold-standard because of the heterogeneity of glioma. Thus, it is necessary to find new criteria independent of conventional morphological diagnosis. Molecular imaging such as positron emission tomography (PET) is one of the most promising approaches to this challenge. PET provides live information of metabolism through the behavior of single molecules. The advantage of PET is that its noninvasive analysis does not require tissue sample, therefore examination can be performed repeatedly. This is very useful for capturing changes in the biological nature of tumor without biopsy. In the present clinical practice for glioma, (18)F-fluorodeoxyglucose (FDG) PET is the most common tracer for predicting prognosis and differentiating other malignant brain tumors. Amino acid tracers such as (11)C-methionine (MET) are the most useful for detecting distribution of glioma, including low-grade. Tracers to image hypoxia are under investigation for potential clinical use, and recently, (18)F-fluoromisonidazole (FMISO) has been suggested as an effective tracer to distinguish glioblastoma multiforme from others.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.